Search for a trial

Phase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia With Safety Run-in (Golden Gate Study)

This study has been transitioned to CTIS with ID 2023-503640-14-00 check the CTIS register for the current data. Primary:• To compare event-free survival (EFS) of subjects receiving blinatumomab alternating with low-intensity chemotherapy to EFS of…

Phase III study comparing R-CODOX-M/R-IVAC versus dose-adjusted EPOCH-R (DA-EPOCH-R) for patients with newly diagnosed high risk Burkitt lymphoma

Primary objective:- To confirm in a multicenter setting an improvement in EFS to 95% at 2 years of DA-EPOCH-R in patients with newly diagnosed high risk Burkitt lymphoma as compared to an expected EFS of 72% at 2 years for the control arm R-CODOX-M/…

Androgen Deprivation therapy for Oligo-recurrent Prostate cancer in addition to radioTherapy

This study has been transitioned to CTIS with ID 2024-511252-41-00 check the CTIS register for the current data. The aim of the current study is to extend the time to develop new disease progression in prostate cancer patients with recurrent disease…

A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator*s Choice of Chemoimmunotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation

This study has been transitioned to CTIS with ID 2023-509349-11-00 check the CTIS register for the current data. Primary objective: To determine the efficacy of the combination of acalabrutinib and venetoclax without obinutuzumab (AV; Arm A), or…

A Phase 3, Open -label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) versus Epoetin alfa for the Treatment of Anemia due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in ESA Naïve Subjects who require Red Blood Cell Transfusions.

This study has been transitioned to CTIS with ID 2022-501485-22-00 check the CTIS register for the current data. Primary objective:• To evaluate the efficacy of luspatercept on RBC transfusion independence (RBC-TI for 12 weeks [84 days] with an…

Development, dIagnostic and prevention of gender-related Somatic and mental COmorbitiEs in iRritable bowel syndrome In Europe

Primary Objective: The overarching goal of the multicentre trial is to characterize the overlap between mental and non-mental comorbid conditions of IBS. In IBS and patient control groups we will characterize depression, anxiety, fibromyalgia and…

A phase III randomized, open-label, multi-centre, global study of Durvalumab and Bacillus Calmette-Guerin (BCG) administered as combination therapy versus BCG alone in high-risk, BCG-naive non-muscle-invasive bladder cancer patients

This study has been transitioned to CTIS with ID 2023-505341-23-00 check the CTIS register for the current data. To assess the efficacy of durvalumab + BCG (induction and maintenance) combination therapy compared to BCG (induction and maintenance)…

Enhancing positive schemas with tdcs: a pilot study

We aim to investigate the relationship between positive schema activation and subsequent tests of emotional schema memory, and whether tDSC during positive schema activation can facilitate retrieval of emotional memory for positive information in…

The Role of Clamping Before Removal of a Pneumothorax Drain Connected to a Digital Drainage System

To demonstrate that removal of drains exclusively based on digital drainage system data is non-inferior to additional clamping trials regarding recurrent pneumothorax requiring chest tube reinsertion.

A Phase 3, Multicenter, Randomized, Platform Study of p19 Inhibition of the IL-23 Pathway to Establish Efficacy in Pediatric Crohn*s Disease;ISA title: A Phase 3, Multicenter, Randomized Clinical Study to Evaluate Mirikizumab in Pediatric Crohn*s Disease

This study has been transitioned to CTIS with ID 2024-511472-32-00 check the CTIS register for the current data. Primary for Platform-Level Exploratory Analysis1. To evaluate whether treatment with IL-23 inhibitors is superior to adult placebo in…

Safety and Viability of an E. coli Nissle Colibactin Knockout in Healthy Volunteers: A Randomised Controlled Safety Study

Assess the safety and tolerability of the EcNΔClbP strain relative to the EcN wildtype strain following a 1-week daily administration, through questionnaires, medical examination and measurement of inflammatory markers.

SUPERvised three-month exercise program in MEN with Prostate cAncer Receiving androgen-deprivaTioN thERapy

To examine the impact of a supervised training program on disease-related quality of life and physical fitness in patient with advanced prostate cancer compared to usual care.

Open-Label, Global, Multicenter, Randomized, Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy

This study has been transitioned to CTIS with ID 2024-512148-50-00 check the CTIS register for the current data. To compare the overall survival (OS) of sacituzumab govitecan (SG) versus docetaxel.

An open-label, randomized, Phase 3 clinical trial of IO102-IO103 in
combination with pembrolizumab versus pembrolizumab alone in patients
with previously untreated, unresectable, or metastatic (advanced)
melanoma

This study has been transitioned to CTIS with ID 2024-511996-13-00 check the CTIS register for the current data. The primary objective is to investigate the efficacy of IO102-IO103 in combination with pembrolizumab (compared with pembrolizumab alone…

A PROSPECTIVE, RANDOMIZED, OPEN-LABEL PHASE 2 STUDY TO EVALUATE THE SUPERIORITY OF INOTUZUMAB OZOGAMICIN MONOTHERAPY VERSUS ALLR3 FOR INDUCTION TREATMENT OF CHILDHOOD HIGH RISK FIRST RELAPSE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKAEMIA

This study has been transitioned to CTIS with ID 2023-509810-13-00 check the CTIS register for the current data. Primary Objectives Efficacy: To demonstrate the superiority of InO monotherapy vs ALLR3 induction in paediatric participants between 1…

A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination with Chemotherapy Versus Pembrolizumab With Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations

This study has been transitioned to CTIS with ID 2023-509825-38-00 check the CTIS register for the current data. To compare the effect of ZIM and DOM in combination with chemotherapy relative to PEMBRO in combination with chemotherapy (Group A…

A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

This study has been transitioned to CTIS with ID 2022-502977-41-00 check the CTIS register for the current data. Primary ObjectiveTo assess the efficacy of furmonertinib compared to platinum-based chemotherapy using progression-free survival (PFS)…

A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting (KEYNOTE-C93/GOG-3064/ENGOT-en15)

This study has been transitioned to CTIS with ID 2023-506361-56-00 check the CTIS register for the current data. This study is designed to assess the efficacy and safety of pembrolizumab monotherapy compared with SoC platinum doublet chemotherapy…

A Phase 3, Multicenter, Randomized, Platform Study of p19 Inhibition of the IL-23
Pathway to Establish Efficacy in Pediatric Crohn*s Disease;ISA title: Efficacy, Safety, and Pharmacokinetics of Guselkumab in Pediatric Participants with
Moderately to Severely Active Crohn*s Disease

This study has been transitioned to CTIS with ID 2023-504735-41-00 check the CTIS register for the current data. Primary for Platform-Level Exploratory Analysis1. To evaluate whether treatment with IL-23 inhibitors is superior to adult placebo in…

Acupuncture for Nasal Congestion in Allergic Rhinitis: An Open-Label, Randomized, Monocenter Trial (ANCAR Trial)

To evaluate the effects of an acupuncture treatment protocol for nasal congestion in AR.